This clinical trial focuses on treating high-risk relapsed neuroblastoma, a type of cancer that has returned after initial treatment or has progressed after being classified as high-risk at any point following diagnosis. The study aims to test new treatments against currently available options for patients whose cancer has returned. The trial will evaluate several medications including temozolomide, topotecan, bevacizumab, dinutuximab beta, and irinotecan.
The study is designed as a platform trial with multiple treatment arms, meaning different treatment combinations will be tested simultaneously. Some medications will be given by mouth, while others will be administered through an intravenous line (directly into the vein). The treatments will be given in cycles, and patients will be monitored for up to 12 treatment cycles.
During the study, doctors will track how well the treatments work by measuring if the cancer stops growing or shrinks, how long patients live without their disease getting worse, and how long they survive overall. They will also monitor side effects and assess quality of life using questionnaires. Patients will have regular medical examinations, including scans and blood tests, to evaluate their response to treatment.
Austria 
Belgium 
Denmark 
France 
Germany 
Italy 
Norway 
Spain 
Sweden 
The Netherlands